Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa
Christophe Le Terrier, Patrice Nordmann, Charlotte Freret, Marion Seigneur, Laurent Poirel
Abstract
The impact of broad-spectrum β-lactamases on the susceptibility to novel β-lactamase/β-lactamase inhibitor combinations was evaluated both in Pseudomonas aeruginosa and Escherichia coli using isogenic backgrounds. Cefepime-zidebactam displayed low MICs, mainly due to the significant intrinsic antibacterial activity of zidebactam. Cefepime-taniborbactam showed excellent activity against recombinant E. coli strains, including metallo-β-lactamase producers, whereas aztreonam-avibactam remained the best therapeutic option against class B β-lactamase-producing P. aeruginosa.
Topics & Concepts
CefepimeAztreonamMeropenemPseudomonas aeruginosaImipenemMicrobiologyEscherichia coliCarbapenemBiologyBroad spectrumAntibioticsChemistryBacteriaAntibiotic resistanceBiochemistryCombinatorial chemistryGeneticsGeneAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPharmaceutical and Antibiotic Environmental Impacts